Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
| Revenue | $2,071,600,000 |
| Net Income | $418,300,000 |
| Free Cash Flow | $305,400,000 |
| Book Value / Share | $17.29 |
| Total Liabilities | $1,876,100,000 |
| Total Equity | $1,211,600,000 |
| Debt / Equity | 1.17 |
| Current Ratio | 3.54 |
| Interest Coverage | 7.23 |
| Working Capital | $1,342,800,000 |
Core multiples and valuation signals — useful to compare vs peers.
| P/E (TTM) | 43.74 |
| Industry P/E | N/A |
| Forward P/E | 80.74 |
| P/B | 15.10 |
| Price / Sales | 8.83 |
| P / FCF | 59.90 |
| EV / EBITDA | 44.28 |
| Graham Number | $48.19 |
| DCF (placeholder) | — |
| Gross Margin | 69.79% |
| Operating Margin | 14.91% |
| Net Margin | 20.19% |
| ROIC | 16.27% |
| Asset Turnover | 0.67 |
| RSI (14) | 43.35 |
| SMA 50 | 324.48 |
| SMA 200 | 292.11 |
| MACD | -3.40 |
| Signal | BULLISH |
| Name | Title |
|---|---|
| Ms. Flavia H. Pease | Executive VP & CFO (1973) |
| Mr. Eric Benjamin | Executive VP & COO (1983) |
| Mr. John Wodick Kapples J.D. | Senior VP & General Counsel (1960) |
| Ms. Ashley A. McEvoy | CEO, President & Director (1971) |
| Mr. Amit Guliani | Chief Technology Officer (—) |
| Ms. Clare Trachtman | Vice President of Investor Relations (—) |
| Ms. Laetitia Cousin | Senior VP of Regulatory Affairs, Quality Assurance & Compliance (1976) |
| Ms. Angela Geryak Wiczek | Senior Director of Corporate Communications (—) |
A Relative Strength Rating upgrade for TransMedics Group shows improving technical performance. Will it continue?
Global equities continued to climb in Q3, finishing the period with double-digit year-to-date gains. Read more here.
Insulet (PODD) shares are catching attention with a recent daily dip of 1.8%, despite gaining 22% for the year. Investors might be weighing the broader trends in the medical device space as they consider the company’s long-term growth trajectory. See our latest analysis for Insulet. Insulet’s share price has pulled back slightly from recent highs, but the company is still riding an impressive wave of momentum, with a year-to-date share price return over 22% and a standout total shareholder...